Breaks Categories: News

WednesdayApr 10, 2019 9:20 am

NetworkNewsBreaks – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) Issues Update on Cannabis Facility Acquisition

TransCanna Holdings (CSE: TCAN) (FSE: TH8), an emerging cannabis branding, transportation and distribution company based in Canada, this morning provided an update concerning the company’s acquisition of a 196,000-square-foot vertically integrated cannabis facility. Per the update, TransCanna expects the closing of escrow for the acquisition to take place on or around Monday, April 15th. The company intends to provide an additional update upon the successful completion of the acquisition. To view the full press release, visit http://nnw.fm/4jQcu About TransCanna Holdings Inc. TransCanna Holdings Inc. is a Canadian-based company focused on providing integrated branding, transportation and distribution services, through its wholly-owned California…

Continue Reading

TuesdayApr 09, 2019 9:36 am

NetworkNewsBreaks – Liberty Defense Holdings, Ltd. (TSX.V: SCAN) Commences Trading on the TSX Venture Exchange

Following completion of a reverse take-over, security solutions and technology company Liberty Defense Holdings (TSX.V: SCAN) today announced that its common shares have commenced trading under the symbol "SCAN" on the TSX Venture Exchange. “We are delighted to be able to commence trading on the TSX Venture under the symbol ‘SCAN’. The completion of the recent reverse takeover and associated financing means that we are well placed to be able to achieve our business objectives in 2019,” Liberty Defense Holdings CEO Bill Riker said in the news release. “We are already having exceptional interest in our HEXWAVE product and look…

Continue Reading

TuesdayApr 09, 2019 9:30 am

NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) CEO to Present at the Cambridge Healthtech Institute’s Inflammation Inhibitors Conference

INmune Bio (NASDAQ: INMB) this morning announced that the company’s co-founder and CEO Dr. RJ Tesi will be presenting at the Cambridge Healthtech Institute’s Inflammation Inhibitors Conference on April 11th at 4:50 PM in San Diego. Dr. Tesi’s presentation titled, “Targeting Soluble TNF to Eliminate Chronic Inflammation without Immunosuppression,” will discuss targeting soluble tumor necrosis factor (“TNF”) to remove chronic inflammation without immunosuppression. “Inflammation, especially chronic inflammation, is being recognized as an important part of the pathophysiology of many diseases, including cancer and Alzheimer’s disease,” INmune Bio co-founder and CEO Dr. RJ Tesi stated in the news release. “Drugs targeting…

Continue Reading

TuesdayApr 09, 2019 9:29 am

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Renews Senior Management Contracts, Cancels Options

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced its successful negotiation of renewal management contracts with chief executive officer Chris Bunka and president John Docherty. According to the update, the new 3-year term contracts, for which specific details can be found within regulatory filings, provide management continuity during this period of corporate growth while allowing the company to seamlessly pursue its business goals and create shareholder value. In addition, Lexaria announced that, effective April 5, 2019, it has reached agreements with certain optionees to cancel 1,140,000 stock options with exercise prices ranging…

Continue Reading

TuesdayApr 09, 2019 9:00 am

NetworkNewsBreaks – Chemistree Technology Inc. (CSE: CHM) (OTCQB: CHMJF) Appoints Cannabis Industry Veteran with Passion, Deep Expertise to its Board

Chemistree Technology (CSE: CHM) (OTCQB: CHMJF) recently announced its appointment of Nicholas J. Zitelli to its board of directors. Zitelli is currently part-owner, director, and chief cannabis officer of Trans High Corporation (“THC”), the parent company for all HIGH TIMES brands, and is also the founder and CEO of the Cannabis Genetics Institute (“CGI”), a well-established research and development institution. Zitelli has authored hundreds of articles since 2007, under the penname of "Nico Escondido,” covering all cannabis science and technology aspects and garnering a reputation as an industry expert in the areas of garden technologies, cultivation, genetics, lab testing, and…

Continue Reading

MondayApr 08, 2019 12:33 pm

NetworkNewsBreaks – GENFIT S.A. (NASDAQ: GNFT) Secures Gross Proceeds of Approximately $155.4 Million through Initial Public Offering

French biopharmaceutical company GENFIT S.A. (NASDAQ: GNFT) recently closed its initial public offering of 7,647,500 new ordinary shares, including an additional 997,500 ADSs pursuant to the full exercise of the over-allotment option granted to the underwriters. The offering, which resulted in gross proceeds of approximately $155.4 million for GENFIT S.A., was comprised of 7,147,500 American Depositary Shares, each representing one ordinary share (“ADSs”), at a public offering price of $20.32 per ADS, and a concurrent private placement of 500,000 ordinary shares in Europe (including France) and countries outside of the United States at the corresponding offering price of €18.00 per…

Continue Reading

MondayApr 08, 2019 11:46 am

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data at 2019 AACR Annual Meeting

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning announced that its collaborators from the University of Texas MD Anderson Cancer Center (“MD Anderson”) detailed positive preclinical data, in a poster presented at the American Association of Cancer Research Meeting 2019, regarding the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer. TUSC2 is a tumor suppressor gene and the active agent in Genprex’s Oncoprex immunogene therapy. “Development of an improved humanized patient-derived xenograft, Hu-PDX, mouse model for evaluation of antitumor immune response in lung cancer,” was the title of the poster,…

Continue Reading

MondayApr 08, 2019 10:14 am

NetworkNewsBreaks – Generation Alpha Inc. (GNAL) Purchases Arizona Cultivation Facility in Effort to Fast-Track Operations in US Medical Cannabis Sector

Vertically integrated cannabis technology innovator, manufacturer and distributor Generation Alpha Inc. (OTCQB: GNAL) this morning announced its purchase of a roughly 46,000 sq. ft. facility in Phoenix, Arizona. According to the update, the facility is approved with a special use permit (“SUP”) for the cultivation and processing of medical cannabis and is ideally located less than 10 miles from Phoenix’s Sky Harbor International Airport. “This is an incredible deal for Generation Alpha,” GNAL CEO Alan Lien commented in the news release. “This facility, which has been locally permitted for medical cannabis cultivation and processing, will allow us to fast track…

Continue Reading

MondayApr 08, 2019 9:46 am

NetworkNewsBreaks – Foresight Autonomous Holdings Ltd.’s (NASDAQ: FRSX) (TASE: FRSX) QuadSight Named ‘Gold Winner’ at 2019 Edison Awards

Automotive technology innovator Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) this morning announced that its QuadSight vision system was recognized at the prestigious 2019 Edison Awards, being named the ‘Gold Winner’ of the ‘Transportation & Logistics, Autonomous Vehicles’ category. Named after Thomas Alva Edison, the awards recognize and honor the world’s best innovators and innovations. A judging panel of more than 3,000 professionals from a wide range of organizations operating in the fields of product development, design, engineering, science, marketing and education selected Foresight’s QuadSight quad-camera stereoscopic vision system for this honor. The system adapts field-proven security technology that…

Continue Reading

MondayApr 08, 2019 9:30 am

NetworkNewsBreaks – INmune Bio, Inc.’s (NASDAQ: INMB) XPro1595 Featured in Poster Presentation at The European Conference on Neuroinflammation

INmune Bio (NASDAQ: INMB) this morning announced that Lesley Probert, Ph.D., Head of Immunology Department at the Hellenic Pasteur Institute in Athens, Greece, will be presenting a poster about new data on INmune’s neurodegenerative disease drug candidate XPro1595 at The European Conference on Neuroinflammation on April 8th and 9th. The presentation is titled “Selective inhibition of soluble TNF promotes macrophage phagocytosis of myelin debris and remyelination of demyelinated lesions” and will shine a light on how XPro1595 promotes remyelination in animal models of Multiple Sclerosis (“MS”), as demonstrated in Dr. Probert’s earlier work. “The work done by Dr. Probert and…

Continue Reading